Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III adjuvant recMAGE-A3 + AS15 in MAGE-A3-positive resected stage III melanoma
2008-002447-16Phase 3Terminated
- Sponsor
- GSK
- Start
- Jul 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing recMAGE-A3 + AS15 with Placebo (2 arms). Primary endpoints: Disease-free survival and Disease-free survival in gene-signature subgroup. Started Jul 2008; status: terminated.
02
Drugs
recMAGE-A3 + AS15
03
Conditions
melanoma
Beyond the preview
Go deeper on 2008-002447-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002447-16.